- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02724085
A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous TP-271 in Healthy Adult Subjects
Study Overview
Detailed Description
Up to seven cohorts of eight subjects each (up to a total of 56 subjects) will be enrolled. The eight subjects within each cohort will be randomized 6:2 to receive a single intravenous dose of TP-271 or placebo. The planned doses are:
Cohort A: 0.15 mg/kg Cohort B: 0.45 mg/kg Cohort C: 1.0 mg/kg Cohort D: 2.0 mg/kg Cohort E: 3.0 mg/kg Cohort F: 4.0 mg/kg Cohort G: 5.0 mg/kg
Doses of IMP will be administered intravenously on the morning of Day 1 following an overnight fast (minimum 8 hours).
During the Screening Period (within the 28 days prior to the subject receiving TP-271 or placebo) each subject will be assessed for eligibility. Each subject must sign and date an ICF prior to undergoing any study-related procedures.
All cohorts will follow the same study design (Figure 1). On Day -1, subjects will be admitted to the study unit so their eligibility can be confirmed. Subjects will be required to stay overnight at the study unit on Day -1. On Day 1, eligible subjects will be enrolled and randomized to receive either TP-271 or placebo. Subjects will be required to stay at the study unit from Day 1 through Day 5 to assess safety and obtain required PK samples. On Day 5, subjects will be discharged from the study unit. A final safety assessment will be performed once between Day 7 and Day 10 following the subject's dose of IMP.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78744
- PPD Phase 1 Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be within the age range of 18 to 50 years, inclusive, at the time of Screening.
- Voluntarily sign an IRB/Research Ethics Committee (IRB/REC)-approved ICF to participate in the study after all relevant aspects of the study have been explained and discussed with the subject and before undergoing any study related procedures.
- Have a body mass index (BMI) ≥18.0 and ≤33.0 kg/m2.
- Be clear of any history of, and have negative screen for, HIV 1 and 2 and hepatitis B and C.
- Have the ability to communicate with the investigative site staff in a manner sufficient to carry out all protocol procedures as described.
- Females must be of non-child bearing potential, either 1-year post-menopausal or surgically sterile (bilateral oophorectomy, bilateral tubal ligation, or complete hysterectomy).
- Male subjects must be willing and able to use a barrier method of birth control or practice abstinence (even if they have had a vasectomy) from dosing through 90 days after the dose of IMP.
Exclusion Criteria:
- History and/or presence of any clinically significant disease or disorder such as cardiovascular, pulmonary, renal, hepatic, neurological, gastrointestinal, and psychiatric/mental disease/disorders, which, in the opinion of the PI, may either put the subject at risk because of participation in the study, influence the results of the study, or influence the subject's ability to participate in the study.
Clinical laboratory values that fall outside the eligibility range specified in the table in Appendix C are exclusionary. For the laboratory values that are not included in Appendix C, values outside of the reference range are exclusionary with the following exceptions:
Low Chemistry Values High Chemistry Values Out of Range UA Out of Range Hematology Bicarbonate (> 18 mEq/L Chloride GGT HDL Cholesterol LDH LDL Cholesterol Phosphorus Triglycerides Chloride HDL Cholesterol LDL Cholesterol Phosphorus Triglycerides High or low specific gravity Cloudy Mucus Crystals Ketones (when blood glucose is normal) Hyaline casts High or low pH
High hematocrit Basophils Monocytes MCV MCHC MCH RBC
Blood pressure and pulse outside of the following ranges are exclusionary:
- Systolic blood pressure 85 - 145 mm Hg
- Diastolic blood pressure 50 - 95 mm Hg
- Pulse rate 45 - 95 beats per minute (bpm)
- Known allergy to tetracycline antibiotics or to any of the excipients in TP-271.
Clinically significant abnormal 12-lead ECG, including the following:
- Rhythm other than sinus, QTc interval using Fridericia's formula (QTcF) >450 msec;
- Evidence of second- or third-degree atrioventricular (AV) block;
- Pathological Q-waves (defined as Q-wave >40 msec or depth >0.4 to 0.5 mV);
- Evidence of ventricular pre-excitation;
- Electrocardiographic evidence of complete left bundle branch block, right bundle branch block (RBBB), incomplete LBBB;
- Intraventricular conduction delay with QRS duration >120 msec;
- ST segment abnormalities unless judged by the Investigator to be non-pathologic.
- History of seizures.
- A history within 3 years of Screening of drug abuse (including benzodiazepines, opioids, amphetamine, and cocaine) or a positive drug result at Screening for any of these drugs of abuse. Also excluded are subjects who test positive for cannabinoids (THCs).
- Use of tobacco, nicotine, or nicotine-replacement products within the 3 months prior to the dose of study drug through the last study visit.
- Typical weekly alcohol consumption of 7 or more alcoholic drinks. One drink is defined as 1 glass of beer (approximately 10 to 12 oz) or 1 can (12 oz) of beer, 1 glass of wine (approximately 4 to 5 oz), or 1 glass of distilled spirits (hard liquor) containing 1 oz of the liquor (1 oz of liquid is approximately 30 mL).
- Alcohol consumption within 48 hours prior to dosing.
- Participation in a clinical trial within 10 half-lives of the prior study treatment or the past 3 months if the half-life is unknown of dose or planned participation in another trial in addition to this one during the trial.
- History of difficulty in donating blood or poor venous access.
- Subject has donated blood (1 unit or 350 mL) within 1 month prior to receiving test material or plans to donate prior to receiving test material or during the trial.
- Use of any prescription or non-prescription medication, including vitamins or herbal medications, within 7 days, or 5 half-lives (if known), whichever is longer, prior to dosing. The use of acetaminophen, naproxen, and ibuprofen is permitted except for within 24 hours prior to dosing. (Note: Subjects must refrain from taking herbal or dietary supplements or prescription drug therapy for the duration of the study.)
- Unwillingness or inability to follow the procedures outlined in the protocol. Subject is mentally or legally incapacitated
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cohort A
IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.15 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
|
TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens.
It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
|
Active Comparator: Cohort B
IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.45 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
|
TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens.
It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
|
Active Comparator: Cohort C
IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
|
TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens.
It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
|
Active Comparator: Cohort D
IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
|
TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens.
It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
|
Active Comparator: Cohort E
IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
|
TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens.
It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
|
Active Comparator: Cohort F
IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 4.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
|
TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens.
It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
|
Active Comparator: Cohort G
IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 5.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
|
TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens.
It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (AE)
Time Frame: Through study completion, appromiximately 39 days
|
The incidence, intensity, and type of adverse events (AE) Outcome measures to be collected in support of the primary objective (safety and tolerability) include:
|
Through study completion, appromiximately 39 days
|
Physical Exams
Time Frame: Through study completion, appromiximately 39 days
|
Changes in physical examination findings
|
Through study completion, appromiximately 39 days
|
Vital Signs
Time Frame: Through study completion, appromiximately 39 days
|
Changes in vital signs
|
Through study completion, appromiximately 39 days
|
Safety Laboratory
Time Frame: Through study completion, appromiximately 39 days
|
Changes in safety laboratory (chemistry, hematology, coagulation, urinalysis) results
|
Through study completion, appromiximately 39 days
|
ECG measurements
Time Frame: Through study completion, appromiximately 39 days
|
Changes in ECG measurements
|
Through study completion, appromiximately 39 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Pharmacokinetic (PK) Analysis
Time Frame: Days 1-5
|
Plasma concentrations of TP-271 and its C-4 epimer TP-9555 for PK analysis
|
Days 1-5
|
Urine Pharmacokinetic (PK) Analysis
Time Frame: Days 1-5
|
Urine concentrations of TP-271 and its C-4 epimer TP-9555
|
Days 1-5
|
PK parameters - Cmax
Time Frame: Days 1-5
|
PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Cmax [The maximum observed plasma concentration]
|
Days 1-5
|
PK parameters - Tmax
Time Frame: Days 1-5
|
PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Tmax [The time from dosing at which Cmax is apparent]
|
Days 1-5
|
PK parameters - C8
Time Frame: Days 1-5
|
PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for C8 [The concentration at 8 hours post-dose]
|
Days 1-5
|
PK parameters - C12
Time Frame: Days 1-5
|
PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for C12 [The concentration at 12 hours post-dose]
|
Days 1-5
|
PK parameters - C24
Time Frame: Days 1-5
|
PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for C24 [The concentration at 24 hours post-dose]
|
Days 1-5
|
PK parameters - AUC(0-last)
Time Frame: Days 1-5
|
PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC(0-last) [The area under the concentration vs time curve from zero to the last measured time point]
|
Days 1-5
|
PK parameters - AUC(0-inf)
Time Frame: Days 1-5
|
PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC(0-inf) [The area under the concentration vs time curve from time zero extrapolated to infinity]
|
Days 1-5
|
PK parameters - AUC%extrap
Time Frame: Days 1-5
|
PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC%extrap [The percentage of AUC(0-inf) accounted for by extrapolation]
|
Days 1-5
|
PK parameters - Lambda-z
Time Frame: Days 1-5
|
PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Lambda-z [Slope of the regression line passing through the apparent elimination phase in a concentration vs time plot]
|
Days 1-5
|
PK parameters - T1/2el
Time Frame: Days 1-5
|
PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for T1/2el [The elimination half-life]
|
Days 1-5
|
PK parameters - CL
Time Frame: Days 1-5
|
PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for CL [Clearance: the volume of plasma cleared per unit time]
|
Days 1-5
|
PK parameters - Vd
Time Frame: Days 1-5
|
PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Vd [The volume of distribution]
|
Days 1-5
|
PK parameters - epimer/parent
Time Frame: Days 1-5
|
The PK parameters of the epimer/parent will be calculated for Cmax and AUC(0-inf).
|
Days 1-5
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TP-271-001
- HHSN272201100028C (OTHER_GRANT: NIAID)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Biomedical Advanced Research and Development AuthorityNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Hospital Universitari Joan XXIII de Tarragona.UnknownPneumonia | Nosocomial Pneumonia | Ventilator-Associated PneumoniaSpain
Clinical Trials on TP-271
-
Tetraphase Pharmaceuticals, Inc.National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Tetraphase Pharmaceuticals, Inc.National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Tetraphase Pharmaceuticals, Inc.National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Aeromics, Inc.CovanceCompleted
-
Emory UniversityCooperative for Assistance and Relief Everywhere, Inc. (CARE)Completed
-
Tarsus Pharmaceuticals, Inc.Completed
-
International Centre for Diarrhoeal Disease Research...CARE Bangladesh; Gram Bikash Kendra (GBK); CARE USARecruiting
-
Jiangsu Simcere Pharmaceutical Co., Ltd.CompletedAcute Ischemic Stroke | Cerebral EdemaChina
-
Sumitomo Pharma America, Inc.TerminatedSarcoma | Ewing Sarcoma | Advanced Solid Tumors | Synovial Sarcoma | Dedifferentiated LiposarcomaUnited States
-
St George's, University of LondonNeovii BiotechWithdrawnMitochondrial Diseases | Inborn Errors of Metabolism | Metabolic Disease